Offensive
发表于 2025-3-28 14:45:55
http://reply.papertrans.cn/19/1866/186527/186527_41.png
Tracheotomy
发表于 2025-3-28 21:43:07
http://reply.papertrans.cn/19/1866/186527/186527_42.png
Frisky
发表于 2025-3-29 01:52:51
http://reply.papertrans.cn/19/1866/186527/186527_43.png
在驾驶
发表于 2025-3-29 04:10:33
http://reply.papertrans.cn/19/1866/186527/186527_44.png
AIL
发表于 2025-3-29 07:23:14
Restatement and Propositions (1968)ase (IDUA) lysosomal enzyme, and MPS Type II is caused by mutations in the iduronate 2-sulfatase (IDS) lysosomal enzyme. Both of these diseases have prominent CNS manifestations. This chapter describes biobetter forms of these recombinant enzymes, and the drug development of IgG-IDUA and IgG-IDS fus
occurrence
发表于 2025-3-29 11:52:01
Event Handling with the Swing Component Set,us, in spite of having an effective treatment for Pompe disease, there remains a critical unmet medical need for a less immunogenic GAA, especially for CRIM-negative babies. New methods for inducing tolerance to GAA have been developed in recent years, which are reviewed here. They include drug-indu
闲聊
发表于 2025-3-29 16:16:36
The New Synthese Historical Librarymixing Herceptin. and Avastin. in 5 % dextrose alone failed to reveal aggregates. However, mixing these formulations with human plasma resulted in the formation of large aggregates. No such aggregation was observed when the antibodies were formulated in 0.9 % NaCl and mixed with human plasma. The ag
无力更进
发表于 2025-3-29 23:31:51
Lebensgeschichten aus der Wissenschaft-epitopes cross-react with native, unmodified proteins, breaking immune tolerance (Griffiths 2008; Omersel et al. 2008, 2011; van Beers et al. 2011; Sauerborn et al. 2010; Jiskoot et al. 2009; Schellekens and Jiskoot 2006). Here, autoantibody generation may lead to autoimmune disorders. Analogous to
抚育
发表于 2025-3-30 03:50:40
Vienna Circle Institute Yearbook and delivery and inform regarding potential liabilities that may be associated with the lead molecule. For biobetters, MA studies also ensure that the lead molecule is indeed “better” with respect to the selected attribute. This chapter outlines the MA strategy, the results of which dictate decisio
不能和解
发表于 2025-3-30 06:53:31
https://doi.org/10.1057/9780230373440r efficacy profile (Foye, Lippincott Williams & Wilkins, Philadelphia, 2008). As a result of protein aggregation or degradation, therapeutic activity can be decreased, increased, or altered to have off-target effects. Protein degradation or aggregation could be facilitated under inflammatory circums